Vericel (VCEL) Stock Forecast, Price Target & Predictions
VCEL Stock Forecast
Vericel stock forecast is as follows: an average price target of $57.33 (represents a 2.69% upside from VCEL’s last price of $55.83) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
VCEL Price Target
VCEL Analyst Ratings
Buy
Vericel Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Aug 26, 2024 | Ryan Zimmerman | BTIG | $55.00 | $50.05 | 9.89% | -1.49% |
Aug 02, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $60.00 | $47.52 | 26.26% | 7.47% |
Jul 16, 2024 | Richard Newitter | Truist Financial | $57.00 | $52.10 | 9.40% | 2.10% |
Jul 05, 2024 | Ryan Zimmerman | BTIG | $56.00 | $46.68 | 19.97% | 0.30% |
Jan 25, 2024 | Samuel Brodovsky | Truist Financial | $51.00 | $42.60 | 19.72% | -8.65% |
Jan 03, 2023 | - | H.C. Wainwright | $37.00 | $25.13 | 47.23% | -33.73% |
Dec 20, 2022 | - | Truist Financial | $25.00 | $23.20 | 7.76% | -55.22% |
Jul 18, 2022 | - | BTIG | $34.00 | $28.20 | 20.59% | -39.10% |
10
Vericel Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 1 | 5 |
Avg Price Target | - | $55.00 | $55.80 |
Last Closing Price | $55.83 | $55.83 | $55.83 |
Upside/Downside | -100.00% | -1.49% | -0.05% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Aug 26, 2024 | BTIG | Buy | Buy | Hold |
Aug 16, 2024 | Cowen & Co. | Buy | Buy | Hold |
Aug 02, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Jul 05, 2024 | BTIG | Buy | Buy | Hold |
Jun 25, 2024 | Cowen & Co. | Buy | Buy | Hold |
Jun 20, 2024 | Cowen & Co. | Outperform | Buy | Initialise |
May 09, 2024 | Truist Financial | Buy | Buy | Hold |
May 09, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Apr 15, 2024 | BTIG | Buy | Buy | Hold |
Mar 26, 2024 | Truist Financial | Buy | Buy | Hold |
10
Vericel Financial Forecast
Vericel Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $65.00M | - | $45.92M | $41.02M | $52.69M | $38.55M | $37.05M | $36.07M | $47.59M | $34.51M | $39.52M | $34.57M | $45.23M | $32.26M | $20.01M | $26.68M | $39.39M | $30.50M |
Avg Forecast | $115.20M | $85.48M | $80.16M | $75.38M | $96.47M | $70.56M | $66.40M | $62.21M | $77.89M | $55.21M | $52.59M | $49.07M | $63.95M | $45.14M | $42.14M | $37.88M | $52.88M | $39.91M | $38.35M | $34.30M | $48.99M | $37.48M | $36.78M | $32.04M | $45.00M | $31.05M | $18.87M | $25.54M | $38.99M | $26.84M |
High Forecast | $119.57M | $88.72M | $83.20M | $78.24M | $100.14M | $73.24M | $68.92M | $65.68M | $79.63M | $55.25M | $52.59M | $49.07M | $66.38M | $45.14M | $43.73M | $39.31M | $54.89M | $39.91M | $38.35M | $34.30M | $48.99M | $37.48M | $36.78M | $32.04M | $45.00M | $31.05M | $18.87M | $25.54M | $38.99M | $26.84M |
Low Forecast | $111.41M | $82.66M | $77.52M | $72.90M | $93.30M | $68.24M | $64.21M | $58.72M | $76.94M | $55.17M | $52.59M | $49.07M | $63.94M | $45.14M | $40.75M | $36.63M | $51.14M | $39.91M | $38.35M | $34.30M | $48.99M | $37.48M | $36.78M | $32.04M | $45.00M | $31.05M | $18.87M | $25.54M | $38.99M | $26.84M |
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 13 | 8 | 8 | 9 | 12 | 7 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | - | 1.09% | 1.08% | 1.00% | 0.97% | 0.97% | 1.05% | 0.97% | 0.92% | 1.07% | 1.08% | 1.01% | 1.04% | 1.06% | 1.04% | 1.01% | 1.14% |
Forecast
Vericel EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 13 | 8 | 8 | 9 | 12 | 7 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $12.73M | - | $-5.96M | $-7.35M | $6.84M | $-5.44M | $-7.89M | $-6.20M | $4.99M | $-4.25M | $-3.02M | $-2.33M | $12.40M | $5.90M | $-6.91M | $-3.38M | $10.07M | $3.95M |
Avg Forecast | $-1.15M | $-851.52K | $-798.52K | $-750.95K | $-961.05K | $-702.89K | $-661.47K | $-619.71K | $-775.94K | $-549.97K | $-523.86K | $-7.44M | $-637.05K | $-449.70K | $-419.74K | $-5.88M | $7.45M | $-1.68M | $-1.61M | $-4.65M | $-2.06M | $-1.58M | $-1.55M | $-2.15M | $-1.89M | $-1.31M | $-793.55K | $-2.53M | $-1.64M | $-1.13M |
High Forecast | $-1.11M | $-823.49K | $-772.24K | $-726.23K | $-929.42K | $-679.76K | $-639.69K | $-584.99K | $-766.46K | $-549.58K | $-523.85K | $-5.95M | $-636.95K | $-449.70K | $-405.93K | $-4.71M | $8.94M | $-1.68M | $-1.61M | $-3.72M | $-2.06M | $-1.58M | $-1.55M | $-1.72M | $-1.89M | $-1.31M | $-793.55K | $-2.03M | $-1.64M | $-1.13M |
Low Forecast | $-1.19M | $-883.85K | $-828.83K | $-779.45K | $-997.53K | $-729.57K | $-686.57K | $-654.33K | $-793.23K | $-550.36K | $-523.86K | $-8.93M | $-661.23K | $-449.70K | $-435.68K | $-7.06M | $5.96M | $-1.68M | $-1.61M | $-5.58M | $-2.06M | $-1.58M | $-1.55M | $-2.58M | $-1.89M | $-1.31M | $-793.55K | $-3.04M | $-1.64M | $-1.13M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -19.98% | - | 14.20% | 1.25% | 0.92% | 3.24% | 4.89% | 1.33% | -2.42% | 2.70% | 1.95% | 1.08% | -6.55% | -4.52% | 8.71% | 1.33% | -6.14% | -3.50% |
Forecast
Vericel Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 13 | 8 | 8 | 9 | 12 | 7 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $12.99M | - | $-5.02M | $-6.34M | $5.92M | $-6.58M | $-8.84M | $-6.91M | $4.53M | $-4.90M | $-3.79M | $-3.29M | $12.22M | $3.62M | $-8.18M | $-4.71M | $9.50M | $3.47M |
Avg Forecast | $26.74M | $5.02M | $2.72M | $2.62M | $18.95M | $1.80M | $347.08K | $-584.11K | $15.09M | $-2.37M | $-4.56M | $-8.51M | $8.52M | $-5.95M | $-7.45M | $-6.73M | $6.77M | $-4.95M | $-5.95M | $-5.32M | $6.96M | $-1.38M | $-4.08M | $-3.03M | $9.87M | $-1.18M | $-10.06M | $-3.53M | $9.58M | $-811.45K |
High Forecast | $28.06M | $5.26M | $2.86M | $2.75M | $19.89M | $1.89M | $364.21K | $876.17K | $17.45M | $-2.27M | $-4.36M | $-6.81M | $9.47M | $-5.69M | $-7.13M | $-5.38M | $8.12M | $-4.95M | $-5.95M | $-4.25M | $6.96M | $-1.38M | $-4.08M | $-2.43M | $9.87M | $-1.18M | $-10.06M | $-2.82M | $9.58M | $-811.45K |
Low Forecast | $25.60M | $4.80M | $2.61M | $2.50M | $18.14M | $1.73M | $332.23K | $-1.75M | $12.26M | $-2.48M | $-4.78M | $-10.21M | $7.58M | $-6.24M | $-7.82M | $-8.07M | $5.41M | $-4.95M | $-5.95M | $-6.38M | $6.96M | $-1.38M | $-4.08M | $-3.64M | $9.87M | $-1.18M | $-10.06M | $-4.23M | $9.58M | $-811.45K |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.52% | - | 0.67% | 0.94% | 0.87% | 1.33% | 1.49% | 1.30% | 0.65% | 3.55% | 0.93% | 1.08% | 1.24% | -3.06% | 0.81% | 1.33% | 0.99% | -4.28% |
Forecast
Vericel SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 13 | 8 | 8 | 9 | 12 | 7 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $30.88M | - | $30.65M | $29.48M | $26.92M | $26.98M | $27.14M | $25.86M | $25.97M | $22.77M | $26.19M | $22.66M | $18.24M | $16.04M | $16.49M | $18.07M | $16.38M | $14.98M |
Avg Forecast | $68.22M | $50.62M | $47.47M | $44.64M | $57.13M | $41.78M | $39.32M | $36.84M | $46.13M | $32.69M | $31.14M | $31.04M | $37.87M | $26.73M | $24.95M | $24.54M | $38.77M | $23.63M | $22.71M | $19.40M | $29.01M | $22.19M | $21.78M | $20.91M | $26.65M | $18.39M | $11.18M | $13.55M | $23.09M | $15.89M |
High Forecast | $70.81M | $52.54M | $49.27M | $46.34M | $59.30M | $43.37M | $40.81M | $38.90M | $47.15M | $32.72M | $31.14M | $37.25M | $39.31M | $26.73M | $25.90M | $29.45M | $46.52M | $23.63M | $22.71M | $23.28M | $29.01M | $22.19M | $21.78M | $25.09M | $26.65M | $18.39M | $11.18M | $16.26M | $23.09M | $15.89M |
Low Forecast | $65.97M | $48.95M | $45.91M | $43.17M | $55.25M | $40.41M | $38.03M | $34.78M | $45.56M | $32.67M | $31.14M | $24.83M | $37.86M | $26.73M | $24.13M | $19.63M | $31.01M | $23.63M | $22.71M | $15.52M | $29.01M | $22.19M | $21.78M | $16.72M | $26.65M | $18.39M | $11.18M | $10.84M | $23.09M | $15.89M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.82% | - | 1.23% | 1.20% | 0.69% | 1.14% | 1.20% | 1.33% | 0.90% | 1.03% | 1.20% | 1.08% | 0.68% | 0.87% | 1.47% | 1.33% | 0.71% | 0.94% |
Forecast
Vericel EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 13 | 8 | 8 | 9 | 12 | 7 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | $0.26 | - | $-0.11 | $-0.13 | $0.13 | $-0.14 | $-0.19 | $-0.15 | $0.10 | $-0.11 | $-0.08 | $-0.07 | $0.27 | $0.08 | $-0.18 | $-0.10 | $0.21 | $0.08 |
Avg Forecast | $0.54 | $0.10 | $0.06 | $0.05 | $0.39 | $0.04 | $0.01 | $-0.01 | $0.31 | $-0.05 | $-0.09 | $-0.11 | $0.17 | $-0.12 | $-0.15 | $-0.15 | $0.04 | $-0.10 | $-0.12 | $-0.12 | $0.14 | $-0.03 | $-0.08 | $-0.04 | $0.20 | $-0.02 | $-0.21 | $-0.08 | $0.20 | $-0.02 |
High Forecast | $0.57 | $0.11 | $0.06 | $0.06 | $0.41 | $0.04 | $0.01 | $0.02 | $0.36 | $-0.05 | $-0.09 | $-0.11 | $0.19 | $-0.12 | $-0.15 | $-0.15 | $0.04 | $-0.10 | $-0.12 | $-0.12 | $0.14 | $-0.03 | $-0.08 | $-0.04 | $0.20 | $-0.02 | $-0.21 | $-0.08 | $0.20 | $-0.02 |
Low Forecast | $0.52 | $0.10 | $0.05 | $0.05 | $0.37 | $0.04 | $0.01 | $-0.04 | $0.25 | $-0.05 | $-0.10 | $-0.12 | $0.15 | $-0.13 | $-0.16 | $-0.16 | $0.03 | $-0.10 | $-0.12 | $-0.12 | $0.14 | $-0.03 | $-0.08 | $-0.04 | $0.20 | $-0.02 | $-0.21 | $-0.08 | $0.20 | $-0.02 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.50% | - | 0.72% | 0.85% | 3.61% | 1.38% | 1.55% | 1.28% | 0.68% | 3.88% | 0.97% | 1.73% | 1.33% | -3.29% | 0.87% | 1.18% | 1.07% | -4.80% |
Forecast
Vericel Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
IPSC | Century Therapeutics | $1.28 | $15.00 | 1071.88% | Buy |
XFOR | X4 Pharmaceuticals | $0.37 | $3.67 | 891.89% | Buy |
RLAY | Relay Therapeutics | $4.80 | $19.40 | 304.17% | Buy |
RGNX | REGENXBIO | $9.56 | $32.00 | 234.73% | Buy |
CLGN | CollPlant Bio | $4.19 | $14.00 | 234.13% | Buy |
PLRX | Pliant Therapeutics | $12.79 | $39.71 | 210.48% | Buy |
DAWN | Day One Biopharmaceuticals | $13.52 | $38.80 | 186.98% | Buy |
STOK | Stoke Therapeutics | $11.61 | $30.60 | 163.57% | Buy |
TERN | Terns Pharmaceuticals | $5.91 | $14.25 | 141.12% | Buy |
SNDX | Syndax Pharmaceuticals | $15.77 | $34.30 | 117.50% | Buy |
MREO | Mereo BioPharma Group | $3.49 | $6.75 | 93.41% | Buy |
KROS | Keros Therapeutics | $53.62 | $102.60 | 91.35% | Buy |
XNCR | Xencor | $23.63 | $42.60 | 80.28% | Buy |
IDYA | IDEAYA Biosciences | $25.86 | $46.58 | 80.12% | Buy |
MRUS | Merus | $43.49 | $77.13 | 77.35% | Buy |
CYTK | Cytokinetics | $51.09 | $83.23 | 62.91% | Buy |
DYN | Dyne Therapeutics | $29.68 | $43.88 | 47.84% | Buy |
CRNX | Crinetics Pharmaceuticals | $55.17 | $70.14 | 27.13% | Buy |
BPMC | Blueprint Medicines | $94.60 | $109.71 | 15.97% | Buy |
RVMD | Revolution Medicines, Inc. Warrant | $56.47 | $60.63 | 7.37% | Buy |
VCEL | Vericel | $55.83 | $57.33 | 2.69% | Buy |